Cerus Appoints Timothy L. Moore to Board of Directors
September 06 2018 - 4:15PM
Business Wire
Cerus Corporation (Nasdaq:CERS) today announced the appointment
of Timothy L. Moore to its Board of Directors. Mr. Moore, who
currently serves as executive vice president, technical operations
for Kite, a Gilead Company, brings over three decades of experience
in engineering, manufacturing, and technical operations in the
biopharmaceutical industry.
“Following an extensive search, we are delighted to welcome Tim
to Cerus’ Board of Directors,” said Daniel Swisher, Chair of the
Board. “Tim brings a wealth of manufacturing operations experience
and an impressive track record of success in helping companies in
the life sciences industry scale their global manufacturing and
supply chain operations. Tim’s extensive experience with plasma
derivative and cell therapy production lines in multiple
geographies will serve Cerus well, as we strive to establish the
INTERCEPT blood system as the global standard of care for
transfused blood components.”
“I am looking forward to joining the Cerus Board and supporting
the Company’s strategic plan, including scaling the operational
infrastructure for INTERCEPT and launching their red cell product,”
commented Timothy L. Moore. “Cerus’ INTERCEPT product portfolio is
set to transform blood safety and availability across the globe,
and I am excited to work with the Company to achieve its next stage
of growth.”
Prior to his current position at Kite where he has led the
global manufacturing effort for the launch of Kite’s revolutionary
Yescarta product, Mr. Moore served 12 years in various engineering,
supply chain and manufacturing leadership roles at Genentech, most
recently as senior vice president and head of global technical
operations, biologics unit. Previously in his career, Mr. Moore
held senior manufacturing, operations, and engineering positions at
CSL Ltd, Armour Pharmaceuticals, and Merck.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in
the field of blood transfusion safety. The INTERCEPT Blood System
is designed to reduce the risk of transfusion-transmitted
infections by inactivating a broad range of pathogens such as
viruses, bacteria and parasites that may be present in donated
blood. The nucleic acid targeting mechanism of action of the
INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile
virus and bacteria, as well as emerging pathogens such as
chikungunya, malaria and dengue. Cerus currently markets and sells
the INTERCEPT Blood System for both platelets and plasma in the
United States, Europe, the Commonwealth of Independent States, the
Middle East and selected countries in other regions around the
world. The INTERCEPT Red Blood Cell system is in clinical
development. See http://www.cerus.com for information about
Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180906005828/en/
Cerus CorporationTim Lee, 925-288-6137Investor Relations
Director
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2023 to Apr 2024